Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
The Townsville Hospital ( Site 0107)(0.0 mi away)Contact
+25 other location
squamous cell carcinoma
metastatic head and neck squamous cell carcinoma
This study is designed to assess the safety and efficacy of lenvatinib in combination with
pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and
efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck
squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and a
programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitor.
The primary hypothesis is that pembrolizumab + lenvatinib is superior to SOC chemotherapy
with respect to ORR per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as
assessed by blinded independent central review.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.